Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
11
×
boston top stories
life sciences
national blog main
national top stories
roche
11
×
biotech
san francisco blog main
san francisco top stories
cancer
clinical trials
deals
boston
fda
investing
raleigh-durham blog main
raleigh-durham top stories
amgen
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
novartis
pfizer
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech ipos
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
eli lilly
What
cancer
drug
medicines
approval
fda
roche
bio
blueprint
gene
intended
ipo
life
patients
research
ret
roundup
startup
team
therapeutics
therapy
address
admits
advantages
ago
alliance
analytics
annual
approves
ash
bar
barcelona
betting
big
billion
biofourmis
biopharma
biotechs
blood
brings
bristol
Language
unset
11
×
Current search:
roche
×
unset
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone